Per-Anders Abrahamsson (Former)
1 – 10 of 125
      - show: 10
 - |
 - sort: year (new to old)
 
        Close
        
            
    
    Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2025
 - 
                        Mark
        A non-invasive 25-Gene PLNM-Score urine test for detection of prostate cancer pelvic lymph node metastasis
    
    
- Contribution to journal › Article
 
 - 2021
 - 
                        Mark
        Androgen deprivation therapy and side effects : Are GnRH antagonists safer?
    
    
- Contribution to journal › Scientific review
 
 - 
                        Mark
        Non-invasive Urine Test for Molecular Classification of Clinical Significance in Newly Diagnosed Prostate Cancer Patients
    
    
- Contribution to journal › Article
 
 - 
                        Mark
        Impact of Cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms
    
    
- Contribution to journal › Article
 
 - 2020
 - 
                        Mark
        Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up
    
    
- Contribution to journal › Article
 
 - 
                        Mark
        Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer
    
    
- Contribution to journal › Scientific review
 
 - 2019
 - 
                        Mark
        Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer : The European Association of Urology Position in 2019
    
    
- Contribution to journal › Article
 
 - 
                        Mark
        The effects of Cernitin® on inflammatory parameters and benign prostatic hyperplasia : An in vitro study
    
    
- Contribution to journal › Article
 
 - 2017
 - 
                        Mark
        Intermittent androgen deprivation therapy in patients with prostate cancer : Connecting the dots
    
    
- Contribution to journal › Article
 
 - 
                        Mark
        Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy
    
    
- Contribution to journal › Article
 
 
